Immunitybio, INC.
Late-stage, cell therapy and immunotherapy co. focused on oncology & infectious disease
Based in CA
AI Overview
With $210K in lobbying spend across 5 quarterly filings, Immunitybio, INC is an active lobbying client. Their lobbying covers 3 issue areas. Active from 2021 to 2022.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2021 | $60K |
| 2022 | $150K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Immunitybio, INC. disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: MED, Science/Technology, Health Issues
New Technologies for Accessible, Durable, and Broadly Protective 2nd Generation Coronavirus Vaccines
Federal support for next generation COVID-19 vaccine technology development, approval and distribution.
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.